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Abstract. Copy number variants (CNVs) account for more polymor-
phic base pairs in the human genome than do single nucleotide poly-
morphisms (SNPs). CNVs encompass genes as well as noncoding DNA,
making these polymorphisms good candidates for functional variation.
Consequently, most modern genome-wide association studies test CNVs
along with SNPs, after inferring copy number status from the data gen-
erated by high-throughput genotyping platforms.
Here we give an overview of CNV genomics in humans, highlighting
patterns that inform methods for identifying CNVs. We describe how
genotyping signals are used to identify CNVs and provide an overview
of existing statistical models and methods used to infer location and
carrier status from such data, especially the most commonly used meth-
ods exploring hybridization intensity. We compare the power of such
methods with the alternative method of using tag SNPs to identify
CNV carriers. As such methods are only powerful when applied to
common CNVs, we describe two alternative approaches that can be
informative for identifying rare CNVs contributing to disease risk. We
focus particularly on methods identifying de novo CNVs and show that
such methods can be more powerful than case-control designs. Finally
we present some recommendations for identifying CNVs contributing
to common complex disorders.
Key words and phrases: Copy number variation, genome-wide associ-
ation study, SNP, hidden Markov model, linkage disequilibrium.
Sebastian Zo¨llner is Professor, Department of
Biostatistics, Department of Psychiatry and Center for
Statistical Genetics, University of Michigan, 1420
Washington Heights, Ann Arbor, Michigan 48109-2029,
USA e-mail: szoellne@umich.edu. Tanya M. Teslovich is
Research Fellow, Department of Biostatistics and
Center for Statistical Genetics, University of Michigan,
Ann Arbor, Michigan, USA.
This is an electronic reprint of the original article
published by the Institute of Mathematical Statistics in
Statistical Science, 2009, Vol. 24, No. 4, 530–546. This
reprint differs from the original in pagination and
typographic detail.
BACKGROUND
Genome-wide association studies (GWAS) have
successfully identified many loci contributing to com-
mon complex diseases, and additional variants con-
tinue to be identified as sample sizes increase. How-
ever, nearly all common single nucleotide polymor-
phisms (SNPs) associated with complex diseases have
small effect sizes and explain only a small fraction
of the heritability of disease [30]. Hence, it is pru-
dent to consider other types of heritable variation
that may account for this unexplained heritability.
One promising candidate is copy number variation
(CNV).
CNVs are segments of the genome that exist in
different copy numbers in the population. Tradition-
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ally, CNVs are defined to be at least 1 kb long [42],
but as the ability to detect these polymorphisms im-
proves, shorter segments are also considered. About
90% of CNVs have two allelic states [35]. By compar-
ison to the NCBI human reference sequence or to a
study-specific reference sample, such biallelic CNVs
are classified as deletions if the alternate allele car-
ries fewer copies of the variable sequence than the
reference, and insertions (or duplications) when the
alternate allele contains more copies than the ref-
erence. The remaining 10% of loci have copy num-
ber states not compatible with a two allelic system,
many of which may be explained by multiple over-
lapping CNVs [35].
Some publications refer to CNVs with apprecia-
ble minor allele frequency as copy number poly-
morphisms (CNPs), and genomic regions containing
multiple overlapping CNVs are called CNV regions
(CNVRs). Here, we will use the term CNV for all
copy number polymorphisms. The cancer commu-
nity has introduced the term copy number alteration
(CNA) for somatic copy number variation; in the
following we focus on germline CNVs.
CNVs are distributed ubiquitously throughout the
genome, with a 25-fold enrichment near segmen-
tal duplications [20, 46]. The reported proportion
of the human genome covered by CNVs varies be-
tween 16% [20] and 5% [35]. Such discrepancies arise
because most CNVs are rare. About 40% of the cov-
ered region described by Itsara et al. [20] shows di-
vergent copy number in only one out of ∼2000 indi-
viduals; CNVs with minor allele frequency (MAF)
> 1% cover less than 1% of the human genome.
Therefore, the number of detected CNVs will de-
pend strongly on the sample size of the study; larger
samples are likely to detect much larger numbers
of CNVs. Moreover, CNV allele frequencies corre-
late with CNV location; CNVs near segmental du-
plications have higher average population frequency
than do CNVs at random loci in the genome [20].
Taken together, these results suggest that more ge-
netic variation is attributable to CNVs than to SNPs
[45]. While several studies have shown that CNVs
encompass genes less often than would be expected
by chance [5, 20], up to ∼2900 genes overlap known
CNVs [42]. Several CNVs have been shown to be as-
sociated with common disorders (reviewed below),
but generally, carriers of genes with aberrant copy
number do not show noticeable clinical phenotypes.
The phenotypic impact of CNVs near or within genes
is generally unclear.
It is of great interest to understand the contribu-
tion of copy number variation to phenotypic diver-
sity in humans, and especially to the risk of com-
mon complex disorders. Several specialized meth-
ods, such as BAC Array Comparative Genomic Hy-
bridization (CGH) [49], Representational Oligonu-
cleotide Microarray Analysis (ROMA) [29] and Ag-
ilent CGH [3] have been developed to detect CNVs.
It is also possible to infer CNVs using data from
genome-wide genotyping arrays. Such approaches are
inexpensive and convenient, since vast amounts of
data generated during GWAS are already available
for analysis. However, the optimal strategy for eval-
uating such data is still an open question.
Below, we will explore existing methods and data
that may inform such strategies. After a brief char-
acterization of genomic patterns of copy number
variation and reported associations between CNVs
and common disorders, we will discuss the signals
generated by genotyping arrays that can be used
to identify CNVs, the methods that exploit one or
more of these signals, and possible pitfalls of these
methods. Based on the genomic patterns of CNVs
and the performance of CNV detection methods, we
will discuss several strategies to identify CNVs con-
tributing to disease risk, and provide approximate
power calculations. Throughout the paper, we will
focus on challenges of analyzing genotype data and
hybridization data such as generated from modern
genotyping platforms.
GENOMICS OF CNVS
In the following, we provide an overview of the ge-
nomic characteristics of CNVs cataloged thus far. To
illustrate several of the described patterns, we sum-
marize data deposited in the Database of Genomic
Variants (DGV) [19], which describes>20,000 struc-
tural variants identified in more than thirty indepen-
dent studies. However, some of the reported data
sets may be conflicting, as many early studies had
high false positive and/or false negative rates, as
well as limited ability to accurately determine the
boundaries of CNVs. As technology improves, pat-
terns are becoming more reliable.
Studies consistently report that CNVs are dis-
tributed ubiquitously throughout the genome [5, 24,
42, 43] while being 25-fold enriched in regions of seg-
mental duplication [20]. Approximately two-thirds
of CNVs in the DGV are deletions, and most stud-
ies included in the DGV report more deletions than
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Fig. 1. Median CNV length for 23 studies in the Database
of Genomic Variants. After excluding polymorphisms <1 kb in
length, we selected all studies with at least 50 polymorphisms
remaining, and median CNV length for each study is repre-
sented by one bar. Bars are color-coded to indicate the method
used to identify CNVs, as indicated by the label on the right.
duplications. It is not clear whether this difference
reflects an actual excess of deletion polymorphisms,
or whether detection methods have more power to
identify deletions. Such a bias is plausible, as most
CNV detection methods rely on hybridization inten-
sities, and the relative difference in intensity due to a
deletion is larger than that corresponding to a dupli-
cation. However, among CNVs > 100 kb in length,
duplications are more frequent than deletions [20].
The DGV contains CNVs as large as 8 Mb, with
a median size of 17.6 kb. The inferred length of a
detected CNV is dependent on aspects of the un-
derlying technology, such as probe spacing, probe
length and signal resolution. To illustrate the differ-
ences between technologies, we calculated the me-
dian CNV length for all studies collected in the DGV
(Figure 1), excluding variants shorter than 1 kb. The
median length of detected CNVs varies a great deal
across studies, and the distribution of CNV length
suggests that BAC arrays and ROMA tend to over-
estimate CNV size. Among studies that report at
least 50 CNVs, the longest observed median CNV
length is 225 kb [43], while the shortest observed me-
dian CNV length is 2.5 kb [26]. The median length
of a study is clearly dependent on its method of
CNV detection. Agilent CGH methods, sequencing
and methods based on Mendelian inconsistencies es-
timate a median length of ∼10 kb, while methods
based on BAC CGH and ROMA suggest a median
length of ∼175 kb. Interestingly, methods based on
SNP chips generate widely varying estimates, rang-
ing from 7.5 kb to 200 kb. Some of this variability
seems to be explained by differences between the
genotyping platforms and the resolution of the al-
gorithms used to analyze the data. As more recent
experimental methods yield much shorter estimates
of median CNV length (even though they should be
well powered to detect longer CNVs), it seems likely
that the CNV lengths reported from BAC CGH ar-
rays and some genotyping arrays are overestimates
[56].
Origin of CNVs
While CNVs are ubiquitous throughout the genome,
we have only limited understanding of their muta-
tion process. The high frequency of CNVs in regions
of segmental duplication suggests that these CNVs
are generated by nonallelic homologous recombina-
tion [54]. By careful analysis of the flanking sequence
of 98 insertions and 129 deletions, Kidd et al. [24] de-
termined that about 40% of those CNVs were caused
by nonallelic homologous recombination. Of the re-
maining insertions, ∼30% were caused by nonho-
mologous end joining, ∼20% by retrotransposition
and ∼10% by expansion or contraction of a vari-
able number of tandem repeats. Among deletions,
∼45% were caused by nonhomologous end joining
and ∼15% by retrotransposition, while a variable
number of tandem repeat regions did not contribute.
These distributions depended on the size of the CNV;
the proportion of CNVs formed by nonallelic ho-
mologous recombination is larger among CNVs > 5
kb. In a recent study, Arlt et al. [1] subjected hu-
man fibroblasts to mitotic replication stress, which
resulted in numerous copy number changes. The au-
thors observed that most breakpoint junctions showed
micro-homologies, suggesting that the copy number
changes were generated by nonhomologous end join-
ing. It is not yet clear if the same processes generate
naturally occurring CNVs. Further work is neces-
sary to estimate the rates of these events and to
understand the contribution of surrounding genetic
motifs. Such understanding may allow us to predict
mutation hotspots for CNV and to estimate muta-
tion rates at these locations. Based on these param-
eters, we can design methods to infer the location of
CNVs and hotspots of de novo mutations. In fact,
several studies have used features of genomic DNA
such as segmental duplications to predict the loca-
tions of CNVs [47, 48].
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Current estimates of the rates of de novo CNV
mutations derive from family studies. CNV status is
inferred for members of a nuclear family, and CNVs
observed in the offspring, but not in the parents,
are assumed to be de novo variants. As both false
positives in the offspring and false negatives in the
parents result in false inference of a de novo event,
it seems likely that the high rates of de novo events
reported in some publications may be the result of
cell line artifacts or affected by the high error rates
of the applied CNV detection methods. In a recent
study that carefully controlled for such errors, Mc-
Carroll et al. [35] observed 10 de novo events in 60
families, suggesting de novo mutation rates of ∼0.08
per generation per genome. When assessing de novo
CNV mutation directly by sperm typing, Turner et
al. [53] estimated rates between 5 · 10−5 and 9 · 10−7
per genome per generation at four likely CNV mu-
tation hotspots selected for their high rates of non-
allelic homologous recombination.
Rates of de novo CNV mutation also are reflected
in the extent of linkage disequilibrium (LD) between
CNVs and flanking markers. If a CNV arises once
during evolution, the LD pattern observed between
the CNV and nearby SNPs is expected to resemble
the pattern of LD observed between pairs of SNPs.
On the other hand, if multiple mutational events
generate apparently identical CNVs, and each mu-
tation event occurs on a different haplotype back-
ground, we expect to observe little or no LD between
the CNV and adjacent markers. Several studies have
suggested that the extent of LD between CNVs and
markers is comparable to the LD between pairs of
SNPs [15, 35], implying a low de novo mutation rate
of CNVs. CNVs in segmental duplications are re-
ported to have less LD with nearby SNPs [28]. It
is unclear whether this reduced LD is truly caused
by a higher rate of CNV mutation in these regions,
or whether this observation is an artifact of reduced
SNP coverage. As SNP density in segmental dupli-
cations is generally lower than in other genomic re-
gions due to the difficulty of designing high-quality
genotyping assays for duplicated SNPs [28], marker
panels are less likely to contain markers with the al-
lele frequency necessary to obtain high values of r2.
Nevertheless, coalescent simulations show that even
relatively high mutation rates of 10−5 are consistent
with high levels of linkage disequilibrium [61].
Frequency Spectrum and Signals of Selection
Mutation rates of some CNVs are several orders
of magnitude higher than mutation rates of SNPs
[36]; therefore, it is remarkable that CNVs show an
excess of rare variants, compared to population ge-
netic predictions [5]. Recently, Itsara et al. [20] re-
ported that in a sample of 2500 individuals, 35% of
all copy number variable sequence was copy num-
ber variable in a single individual. Less than 1%
of CNVs had MAF > 1%. McCarroll et al. [35] re-
ported after analyzing the HapMap sample that only
38% of detected CNVs had MAF > 1%. The same
paper [35] emphasizes that 8% of CNVs responsi-
ble for interindividual variability have MAF ≤ 1%.
This estimate is again consistent with an excess of
rare variants; population genetics models of con-
stant population size predict that 2% of mean differ-
ence between individuals will be generated by poly-
morphisms with MAF ≤ 1%.
Nevertheless, CNVs with appreciable MAF occur
worldwide. Jakobsson et al. [21] explored the distri-
bution of 396 nonsingleton CNV loci inferred in a
worldwide sample of 405 individuals from 29 pop-
ulations, observing that 69% of the detected CNVs
occurred in more than one continental group. Us-
ing the CNVs to form a population history, they
recaptured the same evolutionary history that is in-
ferred from SNP data. In comparison, Kidd et al.
[24] reported that of 1695 CNVs detected in a panel
of four Yoruba, two CEPH, one Chinese and one
Japanese individual, 15% of all CNVs were observed
in two or more continental groups. When analyzing
the HapMap sample using the Affymetrix 6.0 chip,
McCarroll et al. [35] found that 42% of all nonsin-
gleton CNVs were present in more than one conti-
nental group. While the differences between these
estimates may be a result of the different experi-
mental platforms used, the common message is that
a large proportion of common CNVs can be found
worldwide. Whether this wide dispersal of common
CNVs is the result of parallel mutation in multiple
ethnic groups or migration is not clear.
The frequency distribution of CNVs, with its strong
excess of rare variants, can be interpreted as a sig-
nal of purifying selection acting on CNV loci, or as a
signal of population growth. Under a model of pop-
ulation growth we would observe similar allele fre-
quency distributions for CNVs and SNPs, as both
are subject to the same history. However, we observe
a greater excess of rare variants among CNVs than
among SNPs, indicating that purifying selection is
acting to remove many derived CNV alleles from the
population [5, 43]. This theory is further supported
by the finding that rare CNVs are more likely to
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overlap with genes than common CNVs [20]. Similar
evidence has been observed in model organisms: In
inbred mouse strains, Henrichsen et al. [14] reported
a paucity of CNVs in ubiquitously expressed house-
hold genes and an excess of CNVs in genes with
highly variable or tissue-specific expression patterns
as evidence that CNVs are under purifying selection.
Moreover, Emerson et al. [10] reported evidence that
standing copy number variation in Drosophila is re-
duced due to purifying selection. As the selection
acting on CNVs is more pronounced than that ob-
served for SNPs, CNVs are likely to have greater
functional impact than SNPs, negatively affecting
the reproductive fitness of carriers.
Functional Signals of CNVs
Given these signals for purifying selection, it is
unsurprising that several CNVs affecting the risk
of common complex disorders have been reported.
Widely cited is the effect on HIV/AIDS risk of a
copy number polymorphism encompassing the gene
encoding CCL3L1 [13], a potent human immunode-
ficiency virus-1 (HIV-1)—suppressive chemokine and
ligand for the HIV co-receptor CCR5. Lower copy
number of the CCL3L1 gene results in reduced se-
cretion of the CCL3L1 protein and is associated with
increased risk of HIV-1 infection. More recently, re-
duced copy number of the beta-defensin gene cluster
has been reported to be associated with susceptibil-
ity to infectious and inflammatory diseases, particu-
larly Crohn’s disease [11, 34] and psoriasis [16]. Fur-
thermore, results of Willer et al. [59] implicated a 45
kb deletion upstream of NEGR1 as being associated
with body-mass index.
As most CNVs are rare, it can be difficult to demon-
strate a statistically significant association between
a specific allele and disease. Hence, some studies
have examined the association between disease sta-
tus and total CNV load. Rather than testing for as-
sociation between a single CNV and a disease phe-
notype, such analyses assess whether cases have a
significant excess of CNVs (either deletions or inser-
tions) compared to controls. Using this design, Sebat
et al. [44] demonstrated a contribution of deletions
to the risk of autism. More recently, Walsh et al. [55]
reported that de novo insertions contribute to the
risk of schizophrenia, and Zhang et al. [60] presented
similar results for bipolar disorder.
While several risk-CNVs have been detected, the
mechanisms by which these CNVs increase disease
risk are largely unknown. Bridging the gap between
statistical association and biological understanding
is complicated by the fact that even CNVs that
duplicate or delete entire genes may not result in
discernable phenotypes. Moreover, which genes are
affected by a CNV may be hard to predict. Re-
cent studies comparing gene expression and CNVs
across twelve inbred strains of mice demonstrated
that, other than in the CCL3L1 gene, changes in
copy number often have little or no effect on expres-
sion levels [14]. On the other hand, the same study
showed that longer CNVs can alter the expression
of genes over a distance of up to 3 Mb. Thus, CNVs
that contribute to disease risk may do so by acting
on causal genes not normally associated with the
location of the CNV, creating yet another challenge
as we seek to understand the molecular mechanisms
underlying disease risk.
A final challenge of detecting CNVs affecting com-
mon disorders is the small effect size of such CNVs.
Given prior genetic epidemiology experiences with
common complex diseases, we can make predictions
about possible effect sizes of CNVs under different
scenarios. Consider a common CNV (MAF > 5%)
that is tagged by surrounding SNPs. If such a CNV
had a large effect size (OR > 2), the surrounding
SNPs would present a strong signal for association
in a GWAS, and the region would easily be identi-
fied. So far, no such CNV has been detected; CNVs
detected through LD with neighboring SNPs have
small effect sizes, comparable to those of disease-
associated SNPs [34, 59].
Rare CNVs that segregate in the population are
transmitted to offspring according to Mendel’s rules.
Hence, CNVs with effect sizes comparable to those
of variants underlying Mendelian disorders are ex-
pected to generate strong linkage signals. However,
for the last 30 years, geneticists have collected fam-
ilies for common complex disorders and failed to
identify linkage signals that can be explained by
CNV. The absence of strong linkage and associa-
tion signals indicates that there is an upper bound
on the effect size of inherited CNVs that contribute
to complex traits. Population samples are unlikely
to discover inherited CNVs with large effect sizes.
IDENTIFYING CNVS IN GWAS
Given their genomic patterns, CNVs are enticing
candidates for causative variants, and it is of great
interest to identify CNVs associated with common
diseases. As many CNVs are rare, and the effect sizes
6 S. ZO¨LLNER AND T. M. TESLOVICH
of common CNVs are likely to be small, such studies
require large sample sizes. Genome-wide association
studies that type densely spaced panels of SNPs in
large samples of cases and controls are already com-
monplace, and therefore provide an inexpensive re-
source to explore the contribution of CNVs to com-
mon diseases.
The utility of this approach depends on how many
CNVs are covered by the probes on genotyping ar-
rays. Older genotyping arrays type relatively few
SNPs within common CNVs. As markers located
within CNVs are likely to fail multiple quality con-
trol criteria such as HWE, early array designs ex-
cluded such “problematic” markers. Newer genotyp-
ing technologies such as the Affymetrix 6.0 and the
Illumina Human1M-Duo BeadChip have increased
coverage of CNV regions. Even most of the arrays
commonly used today directly interrogate only a
subset of known CNVs. McCarroll et al. [35] re-
ported that only 44% of common CNVs detected in
HapMap samples were represented by at least one
SNP on the Affymetrix 500K or Illumina 650Y ar-
rays, and less than 20% of common CNVs are repre-
sented by three or more SNPs. It has been estimated
that at least 20% of deletions longer than 1 kb span
exactly zero probes on all commercially available ar-
rays [6]. As accurate copy number estimates require
typing multiple SNPs within a CNV, the ability to
infer CNVs directly is limited by this coverage.
Most modern genotyping chips contain dedicated
CNV probes to facilitate copy number estimation.
The Affymetrix 6.0 chip contains 800,000 probes
equally spaced over the genome, as well as 140,000
probes targeted specifically at known CNV regions
[35]; the Illumina Human1M-Duo BeadChip con-
tains 36,000 nonpolymorphic probes to interrogate
known CNV regions. During analysis, such CNV
probes can either be analyzed individually or com-
bined with SNP probes by treating CNV probes
as genotyping probes covering monomorphic SNPs.
Independent of the specific platform, several chal-
lenges must be overcome to perform thorough copy
number analysis using GWAS data. First, the sig-
nal is sparse; >99% of each individual genome is
at normal copy number compared to a reference se-
quence. Second, the signal is noisy, and a single SNP
or probe is usually insufficient to predict copy num-
ber status.
At least three types of evidence have been ex-
tracted from genotyping data and used to infer the
presence of CNVs: (1) Non-Mendelian Inheritance
errors (NMIs) in family data; (2) Departures from
Hardy–Weinberg Equilibrium (HWE); and (3) Dif-
ferences in signal intensity measured during the geno-
typing reaction.
Non-Mendelian Inheritance Errors (NMIs) in
Family Data
Deletions segregating in families can cause the ap-
pearance of non-Mendelian inheritance; hence, NMI
analysis has proven to be a powerful approach to
localize deletions [5, 33]. In most genotyping assays,
hemizygous genotypes are inferred to be homozy-
gous for the present allele. If a hemizygous parent
transmits the deletion-carrying chromosome during
meiosis, the child will be hemizygous and appear to
be homozygous for the allele transmitted from the
other parent. If that allele is different from the allele
observed in the parent transmitting the deletion, the
offspring’s genotype will be inconsistent with his two
parents under Mendel’s rules, and the trio will be
considered to be an NMI (Figure 2). The observation
of multiple consecutive SNPs with non-Mendelian
inheritance in the same trio indicates the presence
of a segregating deletion. However, not all deletions
can be identified through NMI analysis. Carriers in
the parental generation will be identified only if the
chromosome carrying the deletion is transmitted to
the offspring. Even a transmitted deletion will gen-
erate an NMI only if the allele transmitted from the
other parent is inconsistent. The probability of the
deletion being transmitted is 0.5 and the probability
of a transmitted deletion creating an NMI is equal
to the heterozygosity of the SNP. Thus, the prob-
ability of observing an NMI if one of the parents
carries a deletion is equal to half the heterozygos-
ity of the SNP, therefore ≤0.25. Since consecutive
SNPs covered by a deletion are usually in LD, they
do not generate NMIs independently of one another
even when conditioning on the deletion being trans-
mitted. Hence, the probability of seeing any pattern
of NMIs among consecutive SNPs depends on the
haplotype frequencies in the population.
Departures from the Hardy–Weinberg
Equilibrium
Not only will genotyping algorithms generally iden-
tify hemizygous individuals as homozygotes, they
also will call homozygous SNPs in duplicated regions
as heterozygous, if different alleles are present at the
two different loci. Consequently, observed genotype
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Fig. 2. Mendelian inheritance errors. The left panel displays
the genotype of a nuclear family at a single marker; the fa-
ther is hemizygous for a deletion that has been transmitted
to the offspring. The right panel shows the genotypes as they
would be called by a genotyping algorithm. Both hemizygotes
are falsely typed as homozygotes. Note that even though the
actual transmission in the right panel follows Mendel’s rules,
the observed genotypes seem to indicate an impossible inheri-
tance.
frequencies of SNPs covered by deletions or duplica-
tions may show departures from HWE. SNPs within
a deletion will show an excess of homozygous geno-
types for both alleles. Consecutive SNPs all showing
an excess of homozygote calls are indicators of a seg-
regating deletion, and the minor allele frequencies of
SNPs within a deletion will be overestimated from
the data. The expected excess of homozygotes can
be expressed dependent on the frequency of the dele-
tion, and the deletion frequency can be estimated
from the difference between the expected and the
observed number of homozygotes (see the Appendix
for details).
For SNPs covered by duplications, the scenario is
more complicated. SNPs within a duplication usu-
ally will show an excess of heterozygous genotype
calls; the magnitude of this excess depends on the
frequency of the duplication, the distribution of al-
leles that have been duplicated and the LD between
the original region and the duplicate(s). Hence, the
frequency of a duplication cannot be estimated from
genotyping data. In the Appendix, we provide an
overview of the change in genotype and allele fre-
quencies generated by this effect.
Note that such considerations assume uniform be-
havior of genotyping algorithms. For some SNPs
within a duplication, genotype clustering algorithms
may not be able to assign the correct three clusters
to the intensity signal, and produce false genotype
calls or fail to call the SNP. Thus, markers that fail
quality control should be examined carefully to de-
termine whether they lie within CNVs.
Differences in Signal Intensity Measured During
the Genotyping Reaction
Last, we can use the intermediate signal generated
by modern genotyping platforms to infer CNVs. The
two most commonly used high-throughput genotyp-
ing platforms (Illumina and Affymetrix) genotype
by hybridizing the DNA of an individual to a chip,
generating a fluorescent signal for each allele at ev-
ery marker tested. The intensity of this fluorescent
signal depends on the number of alleles present. Due
to the dynamic range of modern arrays, which have
been optimized to yield accurate genotype calls, and
since the scanners used to detect signal become sat-
urated, hybridization intensity is not quite propor-
tional to the number of copies of an allele. Moreover,
the intensity distribution varies between probes and
between genotypes for each probe [62]. Consequently,
it is not obvious how to model the distribution of
hybridization intensities. The intensity of the sig-
nal also depends on all of the usual confounders
of oligonucleotide array analysis such as the total
amount of DNA hybridized, background fluorescence
and hybridization quality [9, 37]. The signal distri-
bution along a chromosome has been described to
show a wave-like pattern easily mistaken for CNVs
[31]. Finally, interpreting this signal is challenging
because the inference of CNV status is confounded
with the genotype calling based on the same sig-
nal. Especially for low-quality DNA data (e.g., from
whole genome amplification), hybridization intensi-
ties are often unsuitable to call CNVs although SNP
genotype calls may be accurate [41].
An important first step in the analysis of hybridiza-
tion data is the normalization of signal intensities.
The raw data usually will consist of one intensity
signal for each of the two possible alleles. The goal
of the normalization step is to transform the two di-
mensional data into a single random variable that
is identically distributed for all loci with baseline
copy number, independent of the underlying geno-
type. For Illumina arrays, this normalization is usu-
ally performed by calculating the Log-R ratio. The
calculation involves outlier removal, followed by nor-
malization against background signal. Based on these
normalized intensities, genotypes are called. The Log-
R ratio (LRR) is the logarithm of the ratio of the
observed signal for a particular individual to the
average signal of individuals in the reference panel
with the same genotype. Hence, individuals with the
same copy number as those in the reference panel
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have LRR ≈ 0, while LRR < 0 indicates a deletion,
and LRR > 0 indicates duplication. This normaliza-
tion algorithm assumes that individuals in the ref-
erence panel have the baseline copy number for all
markers. If this is not the case, the normalization
will be shifted, a problem, especially, for individuals
carrying rare alleles [62]. In addition, Illumina’s nor-
malization procedure provides the B allele frequency
(BAF), a measure for the ratio of intensity signals
between the two genotyping channels. This statistic
can be considered to be a quantitative representa-
tion of genotype, taking values near 0 or 1 for ho-
mozygous genotypes and near 0.5 for heterozygous
genotypes.
For Affymetrix arrays, no equivalent widely-used
normalization strategy exists. While quantile meth-
ods are most often used to normalize the overall hy-
bridization intensity across arrays (e.g., [23]), most
methods analyzing Affymetrix data employ addi-
tional, method-specific normalization algorithms to
account for differences in hybridization intensity dis-
tribution between loci and alleles.
EXISTING METHODS FOR ANALYZING
GWAS DATA
Two possible strategies exist for analyzing the con-
tribution of CNVs to common diseases in GWAS
data. Either CNVs are tested using nearby SNPs as
proxies, or CNVs are inferred from genotyping data,
and the resulting calls are tested for association.
Linkage Disequilibrium (LD) Between CNVs and
Nearby SNPs
As common CNVs in unique regions of the genome
are often in strong LD with neighboring SNPs [15,
35], these SNPs serve as proxies for the linked CNVs,
and SNP genotyping is an accurate and inexpen-
sive alternative to CNV typing. The utility of a
SNP as a proxy measure is dependent on the r2 be-
tween the SNP and the CNV. For CNVs typed in
the HapMap sample [35] and other large population
samples [20], it is possible to define a set of CNVs
that are well tagged by known markers. McCarroll et
al. [35] reported that most common (MAF > 5%),
biallelic CNVs discovered in HapMap samples can
be captured perfectly by at least one SNP in the
HapMap Phase II data (r2 = 1 between CNV and
tag SNP); however, only 30–40% of these CNVs are
tagged perfectly by SNPs on commercially available
genotyping arrays, while 45–65% can be captured by
markers with r2 > 0.8. Similarly, Cooper et al. [6] re-
ported that, among 84 common deletions observed
in eight Yoruba, Japanese, Chinese and CEPH sam-
ples (worldwide MAF > 5%), 82% were tagged by
at least one HapMap Phase II SNP with r2 > 0.8,
and 48–54% were captured (r2 > 0.8) by markers
on commercially available arrays. As standard oper-
ating procedure, GWAS impute all HapMap mark-
ers, using algorithms such as MACH [27], and test
them for association. Consequently, GWAS stud-
ies already test SNPs tagging most common CNVs.
This strategy has been used successfully to identify
CNVs associated with complex traits [34, 59]. How-
ever, this strategy has some weaknesses: First, tag
SNPs cannot be used to infer rare CNV alleles or de
novo events. Second, since most markers on com-
mercial arrays are biallelic, multiallelic CNVs are
necessarily poorly tagged. Third, CNVs located in
segmental duplications are generally more difficult
to tag [35, 46]. For these reasons, the copy number
status of many CNVs must be estimated using other
methods.
Analyzing CNV Calls
Early approaches for identifying CNVs from geno-
typing data focused largely on NMIs and departures
from HWE to identify deletions in HapMap samples
[5, 33]. Kohler and Cutler [22] combined NMIs, de-
viations from HWE and frequency of missing data
to infer deletions from GWAS data.
Presently, most CNV detection methods focus on
analyzing hybridization intensity data, often ignor-
ing other sources of information such as LD or de-
parture from HWE. To identify CNVs, researchers
adapted several methods that were originally de-
signed to analyze cancer data (e.g., circular binary
segmentation, CBS [38]) or designed for other plat-
forms. The first method specifically designed for geno-
typing arrays is an extension of the SW-ARRAY al-
gorithm [39] by Komura et al. [25] to analyze data
from Affymetrix 500K chips. In the recent literature,
hidden Markov model (HMM) methods are the most
commonly applied tool. First proposed by Fridlyand
et al. [12], these methods exploit the local correla-
tion of trait status. As CNVs often extend over mul-
tiple markers, combining information across neigh-
boring markers is often more powerful than looking
at one marker at a time. Colella et al. [4] proposed
an objective Bayes Hidden Markov Model to infer
location and carrier status of CNVs from Illumina
BeadArray data. With PennCNV [56], Wang et al.
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extended this model to utilize information for re-
lated individuals. Such HMM methods have been
applied in many projects (i.e., [20, 21]), and most
CNVs in the databases have been located with these
or similar algorithms. Unfortunately, HMM meth-
ods have relatively high error rates, especially for
shorter CNVs. PennCNV has an error rate of 25%
for CNVs of any length and 9% for CNVs encom-
passing ten or more SNPs [56]. While no error rates
have been reported for other HMM methods, they
are not fundamentally different from PennCNV and,
it is unlikely that they perform substantially better.
Most HMM and CBS methods used to infer CNVs
analyze one individual at a time, and only post-
hoc combine the calls across individuals. While this
keeps the memory requirements for each analysis to
a minimum, it potentially reduces the ability to ex-
ploit occurrences of the same CNV in multiple in-
dividuals. Recently, methods designed under a dif-
ferent paradigm have been published. Rather than
scanning the genome for signals of copy number
variation, these methods only analyze known copy-
number variable regions. Such methods do not have
to account for the uncertainty of the CNV location,
and can therefore generate more precise estimates
of carrier status. The algorithm Canary [23] fits a
Gaussian Mixture model to the intensity distribu-
tion and assigns copy number status according to
cluster membership. Other recent methods attempt
to quantify the uncertainty of the CNV call; such
measures of uncertainty can be incorporated into
tests for association by weighting each call according
to its confidence. CNVEM [62] is based on a similar
idea, using a Bayesian framework to calculate the
posterior probability of copy number, thus account-
ing for the uncertainty in the CNV genotyping. Simi-
larly, Barnes et al. [2] proposed a frequentist method
of modeling copy number states as a latent variable
and then using a mixture model to test for associ-
ation. All of the methods focusing on known CNVs
report substantially lower error rates compared to
HMM models, although few such estimates of error
rates have been replicated independently.
Such methods for calling known CNVs depend
on precise estimates of CNV location. Large col-
lections of CNVs have been described in multiple
databases, including the Database of Genomic Vari-
ants (DGV) [8], the Human Genome Structural Vari-
ation Project [18] and the Copy Number Variation
Project Data Index [7]. Some care must be taken
when selecting loci from these databases; as tech-
nology and algorithms used to detect CNV are still
evolving, these databases contain false positives, and
not all common copy number variants have been de-
tected and reported. Furthermore, the boundaries of
CNVs in these databases may be imprecise, as some
methods for CNV detection only yield approximate
boundaries. In practice, it may be advisable to focus
on CNV collections reported by recent studies, as
these tend to be based on more precise methodology.
Of course, focusing on CNVs reported in databases
is not appropriate when exploring the impact of de
novo CNV mutations, since such variants may not
have been previously observed. In this case, the anal-
ysis can be performed in two steps, with an initial
CNV discovery step using an HMM such as Pen-
nCNV. While such methods may not detect every
CNV in each carrier, it is sufficient to identify each
CNV once in the sample and to generate estimates
of its borders. In a second step, the copy number
status of these CNVs can be called in all individuals
using more precise algorithms.
Comparing Tag SNPs and CNV Calling
It is not obvious whether directly estimating CNV
carrier status is actually a useful strategy if a CNV
is tagged by nearby SNPs; even in the best case,
methods estimating the carrier status of a CNV have
much higher error rates than SNP genotyping [23].
The answer depends on the degree of LD between
the CNV and the proxy SNPs, as well as the er-
ror rate for inferring CNVs directly. Here we as-
sess which approach is more powerful, by determin-
ing the sample size inflation necessary to overcome
power loss due to errors in CNV inferences, and
compare it to the inflation in sample size necessary
to overcome the power loss due to incomplete LD
(r2 < 1). We show that under many scenarios, test-
ing tag SNPs results in a more powerful test than
calling CNVs and testing inferred CNV calls.
Following an argument from Pritchard and Prze-
worski [40], we derive the distribution of a χ2-test
for association based on a 2×2 contingency table de-
pendent on the rate of calling error. Based on that
distribution, we calculate the inflation factor (IF )
by which the sample size needs to be increased to
overcome the loss of power due to CNV calling er-
rors. Assuming no calling error, the distribution of
a χ2-test in a sample of N1 cases and N1 controls is
χ21 =
(P (C|case)− P (C|control ))2N1
2P (C)(1−P (C))
,
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where P (C|case) is the observed frequency of the
minor CNV allele in cases, P (C|control ) is the ob-
served frequency of the minor CNV allele in controls
and P (C) is the overall observed frequency of the
minor CNV allele. Now let O be the event of call-
ing the minor allele of the CNV, C the event of the
minor CNV allele being present and A the event of
the major CNV allele being present. Then we can
parameterize P (O|C) as the probability of correctly
calling the minor allele if the minor allele is present
and P (O|A) as the probability of falsely calling the
minor allele if the major allele is present. Hence,
P (O) = P (O|C)P (C) +P (O|A)P (A)
is the total number of CNVs being called in the sam-
ple. In this model, the χ2-test for association in a
sample of N2 cases and N2 controls is
χ22 = ([P (O|C)−P (O|A)]
× [P (C|case)−P (C|control )])2N2
/(2P (O)(1− P (O))).
To calculate the increase in sample size necessary to
overcome the loss of power due to errors in calling
CNV alleles, we can calculate the inflation factor
(IF ):
IF =
N2
N1
=
1
(P (O|C)− P (O|A))2
P (O)(1−P (O))
P (C)(1−P (C))
.
The right side of the equation indicates the factor
by which the sample size has to be multiplied to
overcome the loss of power due to calling errors.
This inflation factor can be directly compared to
the inflation of sample size necessary to overcome
incomplete LD (r2 < 1), as testing for association at
a marker with r2 = x to the risk variant inflates the
sample size by 1/x [40].
To compare tagging strategies with direct calling
of CNVs, we calculated the inflation factor for a
range of error rates and CNV frequencies commonly
reported in the literature (Table 1). Most CNV call-
ing methods have reported error rates between 0.1
and 0.3. As falsely calling the rare allele of a CNV at
a specific location is unlikely under most methods,
we assumed that most errors were false calls of the
major allele in the presence of the minor allele; the
probability of such errors is (1− P (O|C)); we con-
sider values of P (O|C) between 0.7 and 0.9, for val-
ues of P (O|A) of 0.01 and 0.05. For larger values of
P (O|A), the inflation factor increases rapidly (data
not shown). For comparison, we also calculated the
r2 between the CNV and the best tag SNP that re-
sults in the same inflation factor for the tag SNP
approach.
Our results indicate that calling error reduces the
power of testing rare CNVs more than it reduces the
power of testing common CNVs. Even modest error
rates [P (O|A) = 0.01, P (O|C) = 0.8] increase the re-
quired sample size for finding rare CNVs (MAF =
0.02) by 50% or more, particularly relevant as large
sample sizes are required to detect these rare vari-
ants in the first place (Table 1). Comparison with
LD statistics indicates that, under these conditions,
a SNP tagging the CNV with r2 ≥ 0.49 is sufficient
to provide a more powerful test than inferring CNV
status and directly testing the CNV for association
with disease. Furthermore, a high false positive rate
[P (O|A)] increases the sample size more than does a
high false negative rate (1−P (O|C)). For high val-
ues of P (O|A), inferring and testing a CNV yields
poor results, compared to the tagging method; un-
der all considered parameter combinations, a tag
SNP with r2 ≥ 0.67 to the CNV allows for a more
powerful test for association.
Note that these considerations assume that only
a single tag SNP provides information about the al-
lelic state of the CNV. In practice, we can expect
multiple SNPs to be in LD with the CNV, and com-
bining information across tag SNPs will result in an
even more powerful test statistic. However, when no
tag SNP is available for a particular CNV, valuable
information may be gained by inferring CNV status
directly from GWAS data.
TESTING CNVS FOR ASSOCIATION WITH
DISEASE
After inferring carrier status, several methods can
be used to test for association between inferred car-
rier status and disease. As most CNVs are biallelic,
we can apply methods developed for rejecting the
null hypothesis of no association between a bial-
lelic marker and a phenotype, such as the chi-square
test or logistic regression. In such studies we con-
sider the inferred carrier status to be the true car-
rier status. However, in tests for transmission distor-
tion [17, 50] it should be considered that transmit-
ted CNVs are generally easier to detect than non-
transmitted CNVs, particularly if NMIs are used to
identify carriers. A further potential problem may
be generated by the stringency of the CNV call-
ing algorithm. Commonly, such algorithms impose
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Table 1
Impact of calling error on association testing for common CNVs. We display the inflation factor (IF) for sample size,
necessary to overcome typing error of common CNVs. The first line shows the sample frequency of the rare CNV allele, the
first column shows the probability of falsely calling the rare CNV allele and the second column shows the probability of
correctly calling the rare CNV allele. For each set of parameters the table shows the inflation factor (IF) for the sample size
to overcome the effects of this genotyping error and the LD (r2) to a tag SNP that results in the same loss of power
P (C) (freq. of minor CNV allele)
P (O|A) P (O|C) 0.02 0.05 0.1 0.2
(false positive rate) (sensitivity) IF r2 IF r2 IF r2 IF r2
0.01 0.9 1.74 0.57 1.37 0.73 1.25 0.80 1.20 0.83
0.8 2.05 0.49 1.59 0.63 1.44 0.69 1.40 0.71
0.7 2.49 0.40 1.88 0.53 1.70 0.59 1.66 0.60
0.05 0.9 4.41 0.23 2.45 0.41 1.80 0.56 1.48 0.67
0.8 5.51 0.18 2.99 0.33 2.16 0.46 1.78 0.56
0.7 7.13 0.14 3.77 0.27 2.68 0.37 2.18 0.46
a high burden of proof (e.g., posterior probability
> 0.95) before assigning the minor allele, in order
to minimize the effects of measurement error. This
approach can increase the number of false negative
calls and introduce nonrandom missingness, thus in-
flating the false-positive rate of a family-based test
for association [2].
Tests for association can be improved by account-
ing for the uncertainty in the estimate of carrier sta-
tus. Bayesian methods will generally provide a pos-
terior probability for carrier status [2, 62], and in
frequentist inference methods this uncertainty can
be ascertained by bootstrap or jackknife procedures.
Once this uncertainty is known, tests for association
can be adjusted accordingly. For Bayesian estimates
we can compare the summed expected posterior car-
rier status in a χ2 test or in a logistic expression.
Finally, Stranger et al. [52] skip the step of infer-
ring CNV status for such regions and directly test
for association between hybridization intensity and
case-control status. This method is susceptible to
false positives due to shifts in mean and/or variance
of the underlying intensity distributions, and such
shifts occur frequently in practice [2].
ALTERNATIVE STRATEGIES TO
ASSOCIATION MAPPING
As most CNVs have low MAF, tests for associa-
tion between a single CNV and a disease are likely to
have low power, especially if p-values are corrected
for multiple tests. Therefore, alternative strategies
must be considered. Here we present two such strate-
gies: first a test for an excess of de novo CNV mu-
tations at a locus and second a test for an excess
loading of minor CNV alleles in cases compared to
controls.
Detection of de novo CNVs
As recent results indicate that de novo CNV mu-
tations are rare [35], multiple de novo mutations in
the same region of the genome suggest candidates
for risk variants. However, even if de novo mutations
are over-represented and highly penetrant among
cases, the combined variants at one locus are still un-
likely to have allele frequency > 1% in cases. Hence,
applying standard testing strategies to compare al-
lele frequencies between cases and controls will be
underpowered. Consider, for example, a genomic re-
gion carrying 6 de novo mutations in 1000 cases, and
none in 1000 controls. Testing for association yields
a Fisher’s exact p-value of 0.015, no clear evidence of
association. However, this p-value does not account
for the observation that the rate of de novo muta-
tions is low and therefore the probability of observ-
ing 6 de novo deletions at the same locus by chance
is unlikely.
Nevertheless, it is not clear how many de novo
mutations must be observed in the same region be-
fore the finding is significant. Such a critical value
depends on two parameters: the rate of de novo mu-
tation, and the number of locations in the genome
where such mutations occur. While the mutation
rate can be estimated from existing data sets, early
estimates of these rates were confounded with high
false negative rates [57]. Recent studies suggest that
these rates may be as low as 0.08 per genome per
meiosis [35].
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Estimating the second parameter, the number of
genomic regions experiencing de novo CNV muta-
tion, is more challenging. About 40% of CNVs are
generated by nonallelic homologous recombination
[24], which is caused by flanking repetitive elements
and segmental duplications. Such segmental dupli-
cations cover 5% of the genome. Thus, it is likely
that most nonpathogenic de novo mutations occur
in only a small subset of the genome. However, bet-
ter understanding of the processes generating CNVs
are necessary for a precise estimate of the subset of
the genome with high CNV mutation rate.
To explore the power of detecting a risk variant
by observing an excess of de novo mutations, we
performed computer simulations based on the two
parameters described above. We set the de novo mu-
tation rate of noncausal CNVs to µ per meiosis per
genome, uniformly distributed over k locations in
the genome. We further assumed that a subset ε, of
all de novo CNV alleles would be identified. We did
not model other sources of error, as false positive de
novo CNV calls, by definition, are not expected to
cluster at particular loci in the genome, and there-
fore do not affect our test statistic.
Assuming a sample of n nuclear families, we mod-
eled as the null distribution the total number of
detected noncausal de novo CNVs, ci, at each lo-
cation i, as Poisson-distributed with rate 2µnε/k.
Defining M = max{ci : i = 1, . . . , k} as the maxi-
mum number of noncausal de novo mutations ob-
served anywhere in the genome, the critical value
for a test of an excess of de novo CNVs is equal to
CVα =min{x : P (M ≥ x)<α}. Note that the alpha
level chosen here is the experiment-wide type I error
rate; by maximizing M over all CNV mutation hot-
pots, we have corrected for genome-wide multiple
testing.
To simulate the distribution of causal de novo mu-
tations at a risk locus, we set p as the proportion of
cases in the population carrying the de novo CNV
mutation at a specific risk locus. Then the power for
a test of excess de novo mutations can be calculated
using the binomial distribution, B(εp,n).
We assessed the power of this method to detect
a significant excess of de novo mutations. We first
calculated critical values for sample sizes of n =
500, 1000 and 2000 nuclear families, assuming a de
novo mutation rate of noncausal CNVs of µ = 0.1
per meiosis per genome, uniformly distributed over
k = 500 or 2000 locations in the genome. Assum-
ing an average length of 50 kb per CNV, these val-
ues of k correspond to 0.8% or 3.2% of the hu-
man genome being CNV mutation hotspots, with
CNV mutation rates similar to the rates observed
at hotspots of nonallelic homologous recombination
[53]. We set an error rate for CNV typing of ε =
0.75. Based on the resulting critical values, we cal-
culated the power of observing a significant result
at α= 0.05, assuming that de novo CNVs occur in
p = 1%, 0.5% or 0.25% of all cases at a particular
risk locus. These values are consistent with reports
that de novo CNVs thought to contribute to the risk
of psychiatric diseases are observed in 0.2% to 1%
of all cases [51, 53, 58]. For comparison, we calcu-
lated the total sample size necessary to achieve 80%
power in a balanced case-control design at a signifi-
cance level of 10−5 for all values of p, assuming that
the CNV has full penetrance and is not observed
among controls.
Our results (Table 2) indicate that observing a
large number of CNV mutations at a single locus is
unlikely. Under all considered scenarios, observing 6
or more de novo CNVs at one locus constitutes a
significant result. For sample sizes >1000 trios, we
have reasonable power to detect de novo CNVs that
are present in 0.5% of the cases. The results indicate
that the power of this approach strongly depends on
the total number of CNV mutation hotspots, which
is unknown for the human genome. However, even
if only 500 CNV hotspots exist genome-wide, for a
CNV observed in 1% (0.5%) of all cases, only 1000
(2000) trios are necessary to achieve ∼80% power.
For comparison, 5500 (11,000) unrelated individuals
are required to achieve similar power. This suggests
that testing for an excess of de novo mutations is a
more powerful strategy than case-control testing.
CNV Load of Rare Variants
As discussed previously, most minor alleles of CNVs
are rare, and tests of association between rare vari-
ants and a phenotype have limited power. However,
it is conceivable that multiple, independent CNVs
each contribute to disease risk. Jointly testing all
CNVs may therefore be more powerful than testing
markers individually. If all such risk CNVs cover the
same genomic interval, the contribution of that re-
gion can be determined by counting the number of
individuals who carry a minor allele of any CNV
overlapping with the region. The counts in cases
and controls can then be compared [32], essentially
treating all overlapping CNVs as a single risk al-
lele. Such joint analysis of multiple CNVs is more
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challenging under a model of genetic heterogeneity,
which assumes that a large number of unlinked loci
in the genome are affected by CNVs that contribute
to the risk of disease. Under this model, testing each
individual locus may not result in a significant sig-
nal. However, as the total number of CNVs in an
apparently healthy individual is small [35], if sev-
eral CNVs contribute to the risk of disease, cases as
a whole may carry substantially more minor CNV
alleles than do controls. Therefore, a commonly ap-
plied test is to count the number of minor CNV
alleles observed genome-wide in cases, and compare
that to the number of minor CNV alleles in controls.
While such a test is more powerful under a model of
genetic heterogeneity, it has two weaknesses. First,
it is very sensitive to any experimental error affect-
ing cases and controls differentially. For example,
batch effects can increase the total number of CNVs
observed in one batch over the next. If cases and
controls are analyzed in different batches, such ef-
fects will immediately cause significant genome-wide
differences in CNV numbers between cases and con-
trols. Second, this test lacks interpretability. A sig-
nificant signal only indicates that CNVs somewhere
in the genome increase disease risk. Further testing
of larger samples is required to understand the con-
tribution of individual CNVs. CNVs that show an
excess of minor alleles in cases that is not statisti-
cally significant may be good candidates for further
tests in larger samples.
This strategy has been used successfully to iden-
tify CNVs affecting autism. Initially, Sebat et al. [44]
observed a genome-wide excess of CNVs in autism
patients, but no individual CNV or locus was sig-
nificant after multiple test correction. Further work
by Weiss et al. [58] in larger samples demonstrated
that several of the loci showing suggestive evidence
in the original report [44] are significantly associated
with the risk of autism.
CONCLUSIONS
Copy number variation accounts for much of the
genetic variation discovered to date in humans. Some
of this variation is clearly functional; studies in re-
cent years have discovered several CNVs contribut-
ing to the risk of common complex diseases such as
autism [44] and psoriasis [16]. Hence, studying the
contribution of CNVs to common diseases has be-
come standard practice during the course of genome-
wide association studies. As the genotype and hy-
bridization signals generated by genotyping platforms
provide information about CNVs, it is efficient to
use this signal to infer CNV location and carrier sta-
tus in the sample. Most studies that impute CNVs
from genotype array data focus on analyzing hy-
bridization data. Such analyses require careful nor-
malization of the intensity data, as hybridization sig-
nals are susceptible to experimental noise that may
lead to false inferences.
Many methods have been developed to localize
CNVs using such hybridization intensity data (e.g.,
[25, 56]). While such methods generally perform well
for CNVs covered by large numbers of probes, they
tend to have higher error rates for CNVs that span
only a few genotyped probes [56]. The high error
rates are in part due to the fact that these meth-
ods aim to jointly localize CNVs and determine car-
rier status in individuals, thus increasing the un-
certainty of the inference procedure. As databases
now contain >20,000 CNVs, many of which have
Table 2
Critical values and power in tests for de novo mutations. The first row indicates the number of sites for noncausal CNVs,
and the second line displays the sample size. The third line shows the number of CNVs in one location constituting a
significant number of de novo CNVs. The next three lines show the power to detect a locus carrying an excess of de novo
mutation, assuming that these de novo mutations can be observed in 1%, 0.5% or 0.25% of all cases. The last column
provides the sample size necessary to detect the CNV with 80% power in a case-control design at a significance level of 10−5
Number of de novo CNV mutation hotspots
500 2000
Sample size 500 1000 2000 500 1000 2000 Case-control sample size
CVα 4 5 6 3 4 5
1.00% 0.52 0.86 >0.99 0.72 0.94 >0.99 5500
0.50% 0.12 0.32 0.76 0.29 0.52 0.94 11,000
0.25% 0.02 0.04 0.18 0.07 0.12 0.52 22,000
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been observed more than once in different samples,
it seems likely that most common CNVs are now
known and that CNVs not yet present in databases
are rare, at least in Caucasians. Consequently, al-
gorithms have been developed that, using GWAS
data, infer copy number for CNVs whose bound-
aries are known [23, 62]. Such algorithms are more
precise in calling common CNVs and therefore facil-
itate more powerful tests for association. However,
it is still necessary to apply more general algorithms
to detect unknown CNVs, rare CNVs and de novo
events.
Most CNVs are in strong LD with SNPs in the
HapMap, and it is not always clear that inferring
CNVs to test for association is the most powerful
strategy. As we have shown, even modest error rates
in CNV calling result in a loss of power comparable
to testing a tag SNP with r2 ≤ 0.8. Consequently,
tests based on inferred CNV alleles are often unlikely
to be more powerful than testing surrounding SNPs
for association. In this context, it is interesting to
note that both common risk CNVs identified to date
through genotype scans were first localized via tag
SNPs; only follow-up testing identified these CNVs
as likely risk alleles [34, 59].
On the other hand, this observation also indicates
that SNPs flanking a CNV can provide information
about CNV carrier status, suggesting that existing
methods for calling CNV alleles could be improved
by jointly considering haplotype background and hy-
bridization intensity of the covered markers. As hap-
lotype background and hybridization intensity pro-
vide orthogonal evidence for CNV status, such a
method would likely be substantially more precise
and allow more powerful tests.
Maximizing the power of tests for association is
crucial, as the effect sizes of common CNVs are likely
to be small, and the minor alleles of most CNVs
are rare. Hence, tests for association between CNVs
and diseases are likely to have low power even under
the best circumstances. Other strategies to identify
CNV contributing to the risk of common diseases
should also be explored. Recent studies have indi-
cated that de novo events generating new CNVs are
rare [35]. This suggests that testing a genomic re-
gion for an excess of de novo CNVs is potentially a
powerful strategy. Moreover, such de novo CNVs are
more likely to have large effect sizes. Several such
CNV regions have in fact been detected [44, 55].
We have presented calculations, based on conserva-
tive estimates, that for moderate sample sizes, sim-
ple tests for local excesses of de novo mutations
have good power to identify such CNV mutation
hotspots. However, commonly collected samples of
unrelated cases and controls do not provide any in-
formation as to whether a CNV observed several
times among cases and not in controls is the result
of several de novo mutations or just a result of sam-
pling variation on a rare CNV. Hence, the power
to detect a rare risk variant that is the result of
multiple de novo events is substantially higher in
family-based studies.
Any CNV-disease association identified using geno-
typing chips has to be evaluated carefully. While
analyzing the hybridization signal from genotyping
platforms provides cheap information about CNV
status in a population, genotyping arrays are not
the gold standard for determining carrier status. In
association studies, erroneous calls of carrier status
usually result in a loss of power, rather than false
positive associations. However, in a study testing for
an excess of de novo mutations, even a few inaccu-
rate CNV calls can lead to false positives. Hence, if
a CNV appears to be associated with a phenotype,
it seems prudent to use an independent technology,
such as CGH, PCR or resequencing, to verify the
inferred carrier status and the association signal.
In the near future, GWAS will be supplemented
with studies that sequence regions of interest or even
the entire genomes of affected and unaffected in-
dividuals. Paired end-sequencing allows the detec-
tion of regions where the distance between two short
reads is significantly longer or shorter than expected;
such regions are likely to carry CNVs. In the case of
single-end sequencing, it is necessary to infer CNVs
by indirect measures, such as the number of reads
generated for each region. As read-lengths increase,
it becomes easier to align reads, and it may be-
come possible to identify CNV breakpoints within
a read. Then it will be possible to identify such fea-
tures from the generated sequence. As technology
advances at an incredible pace, we will constantly be
challenged to develop newer, better statistical tools
to infer the presence and location of CNVs.
Ultimately, to understand the role that CNV plays
in human disease, we must better elucidate the bio-
logical processes that create CNV, improve the sen-
sitivity and specificity of experimental methods that
identify CNV, and develop statistical methods that
fully leverage the signals of CNV that exist in data
derived from genome-wide genotyping arrays as well
as next-generation sequencing technologies.
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APPENDIX
In the following we will explore patterns of geno-
type frequencies and the Hardy–Weinberg equilib-
rium in SNPs covered by CNVs. We consider the
observed haplotype frequencies P (G=AA), P (G=
AB), P (G = BB) of a SNP with alleles A and B.
Let p be the population frequency of allele A and
q the allele frequency of allele B. We first consider
deletions, then duplications.
Deletions
We introduce the segregating deletion as a third
genotype D with frequency d, so that d + p + q =
1. Let G ∈ {AA,BB,AB} indicate the possible ob-
served genotypes and T ∈ {DD,AA,AD,AB,
BD,BB} be the set of all possible true genotypes.
Genotype DD will result in a failed genotyping re-
action and hence will never be observed.
Then, assuming no genotyping error for nondele-
tion alleles,
P (G=AA) = P (T =AA|T 6=DD)
+P (T =AD|T 6=DD)
= (p2 +2dp)/(1− d2),
P (G=BB) = P (T =BB|T 6=DD)
+P (T =BD|T 6=DD)
= (q2 +2dq)/(1− d2),
P (G=AB) = P (T =AB|T 6=DD)
= 2pq/(1− d2).
Note that the estimated frequency of allele A is
pest = P (G=AA) + 1/2P (G =AB)
= (p+ dp)/(1− d2) = p/(1− d),
so that we will observe fewer than the expected num-
ber of heterozygotes, given the estimated allele fre-
quencies: 2pestqest = 2pq/(1 − d)
2 ≥ 2pq/(1 − d2) =
E(G=AB).
In a sample of n individuals with observed geno-
type counts (CAA, CAB , CBB), the expected depar-
ture from HWE is
E((CAB)
2 − 4CAACBB)
= Var(CAB) + E(CAB)
2
− 4[E(CAA)E(CBB) +Cov(CAA,CBB)]
= npq/(1− d2) + 8ndpq(1− n)/(1− d).
Insertions
We consider a model where every haploid copy of
the genome carries 0 or 1 insertions. Let T ∈ {A,B}
indicate the true genotype at the original location
and I ∈ {A,B} indicate the genotype at the du-
plication. To account for possible LD between the
inserted region and the original copy, as insertions
can happen multiple times, we consider the proba-
bility of carrying the insertion allele conditional on
the allele at the original location, Q(I|T ). We de-
fine D ∈ {0,1,2}, the total number of insertions on
both chromosomes, and the probability of carrying
a duplication is dT :
P (G=AA)
= P (T =AA)[P (D = 0|A)
+ P (I =A)P (D = 1|A)
+ P (I =AA)P (D = 2|A)]
= p2[(1− dA)
2 +2dA(1− dA)Q(A|A)
+ d2AQ(A|A)
2]
= p2(1− dAQ(B|A))
2,
P (G=BB) = q2(1− dBQ(A|B))
2.
Hence, P (G = AA) = P (T = AA) = p2 iff Q(A|
A) = 1 or dA = 0. Similarly P (G = BB) = P (T =
BB) = q2 iff Q(B|B) = 1 or dB = 0. No departure
from HWE is generated if all duplications with the A
allele occur on chromosomes carrying the A allele at
the original location (likewise for allele B), regard-
less of the frequency of the insertion. This pattern
may be observed if duplications are the result of
nonallelic homologous recombination or other mech-
anisms creating tandem repeats.
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